- Patented UST process produces highly stable, clean and cost-effective nanoemulsions
- Technology can be applied across many industries, including pharmaceutical, food, nutraceutical, industrial lubricant, paint and cosmetic sectors
- UST technology aligns with consumer demand for chemical- and preservative-free products
The demand for nanoemulsions is growing at a fast pace, with potential applications in many industry sectors, including food, pharmaceuticals, nutraceuticals, cosmetics and industrial lubricants. Up to now, one of the major problems with nanoemulsions has been their instability. This instability compromises the bioavailability and absorption of active ingredients for product preparation and the shelf life of the product. Life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) is positioned to change this landscape via a patented novel technique called Ultra Shear Technology (“UST”). This technology uses intense shear forces generated by high-pressure valve discharge, which can help produce nanoemulsions that exhibit significantly improved absorption, greater stability and increased bioavailability compared to traditional micro and macro-emulsions.
Emulsions are mixtures of two liquids which are largely immiscible without the aid of emulsifying chemicals, such as surfactants. Surfactants assist in the dispersion of one liquid within the other, where it exists as tiny droplets. The smaller the droplet size for any given volume of dispersed liquid, the greater the absorption and bioavailability of active compounds. Nanoemulsions produce dispersed droplets with exceptionally small diameters, measured in nanometers.
To date, cost-effective, highly stable nanoemulsions made with minimal or no surfactants have been difficult to produce. Pressure BioSciences’ UST enables manufacturers to produce nanoemulsions at industrial scale levels that virtually exclude the use of surfactants, leading to safer and more effective oral delivery of food and medical products. This is a big deal in today’s world, where consumers across the globe are focusing more on wellbeing and demanding food that is appealing, tastes good, is free of chemicals and is safe to eat. Nanoemulsions produced using UST facilitate the production of food products with enhanced shelf lives and without the need for chemicals or preservatives. This groundbreaking technology will also increase product quality and shelf life in the pharmaceutical, nutraceutical and cosmetic sectors.
In October 2017, Pressure BioSciences concluded a strategic collaboration agreement with Phasex Corporation that will allow for the production of stable, water-soluble nanoemulsions that are expected to significantly improve drug and active ingredient delivery in the pharmaceutical, nutraceutical and cannabis oil industries. Aqueous nanoemulsions have the potential to increase the absorption and bioavailability of water-insoluble compounds like vitamin A, vitamin C and cannabinoids such as CBD. Phasex’s expertise lies in supercritical fluid (“SCF”) extraction processes that can be used for the manufacture of an extensive range of fine chemicals, polymers and natural extracts for pharmaceutical and nutraceutical formulations. SCF technology enables solvent-free extraction of active ingredients, which substantially enhances the quality of nanoemulsions.
Although the UST platform offers very exciting opportunities for future growth, Pressure BioSciences is not dependent on its novel UST platform for its future success. To that point, the company has been showing solid growth over the past several years in its’ primary product line, which is based on its innovative, patented, enabling platform called Pressure Cycling Technology (“PCT”). This technology uses cycles of hydrostatic pressure from ambient to ultra-high pressure levels to control bio-molecular interactions. It can be applied in several emerging life science areas, including:
- Sample preparation for genomic, proteomic and small molecule studies
- Control of biochemical reactions
- Protein purification
- Pathogen inactivation
- Immunodiagnostics
Patents for this technology have been issued to PBIO from many countries around the world, including China, Japan, multiple European countries, Canada, and the U.S. To date, the company has installed almost 300 PCT systems in more than 150 pharmaceutical, academic, biotechnological and government laboratories worldwide. Primary applications for the technology are in biomarker discovery, forensics, pathology and agriculture. The company has reported annual revenue of greater than $2 million, even though it has had but one sales person and one PCT instrument to sell. Recently, however, the company added four additional sales reps and has announced plans to release up to four additional instruments in 2018. These changes have set the company up for what could be significant future growth and an excellent return on investment for shareholders.
For more information, visit the company’s website at www.PressureBioSciences.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
